Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea

Antonia Barceló, Javier Piérola, Cristina Esquinas, Mónica de la Peña, Meritxell Arqué, Manuel Sánchez-de la Torre, Alberto Alonso-Fernandez, Ferran Barbé
European Respiratory Journal 2012 40: 1046-1048; DOI: 10.1183/09031936.00011912
Antonia Barceló
*Servei d'Anàlisis Clíniques, Hospital Universitari Son Espases
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: antonia.barcelo@ssib.es
Javier Piérola
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
¶Unitat d'Investigació, Hospital Universitari Son Espases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Esquinas
+Servei de Pneumologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mónica de la Peña
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
§Pneumologia, Hospital Universitari Son Espases, Palma de Mallorca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meritxell Arqué
§Pneumologia, Hospital Universitari Son Espases, Palma de Mallorca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Sánchez-de la Torre
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
+Servei de Pneumologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Alonso-Fernandez
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
§Pneumologia, Hospital Universitari Son Espases, Palma de Mallorca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferran Barbé
#Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola
+Servei de Pneumologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Obstructive sleep apnoea syndrome (OSAS) has been increasingly linked to cardiovascular disease. fetuin-A is an inhibitor of vascular calcification and an anti-inflammatory cytokine. We tested the hypothesis that plasma levels of fetuin-A are decreased in patients with OSAS.

We studied 119 patients with OSAS and 35 controls. Participants were recruited and studied at the sleep unit at Hospital Universitari Son Espases, Palma de Mallorca, Spain. Serum levels of fetuin-A, glucose, triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma glutamyltransferase (GGT) were determined.

Plasma fetuin-A levels were significantly lower in patients with OSAS than in controls (mean±sd 368±66 versus 445±53 ng·mL−1, p=0.015). In multivariate analysis, fetuin-A levels were independently associated with OSAS (p=0.034). OSAS is associated with reduced levels of fetuin-A and fetuin-A could be one of the contributing factors for the development of cardiovascular complications in OSAS patients.

There is evidence that patients with OSAS have an increased risk for cardiovascular diseases [1]. The mechanisms underlying this association are unclear but candidate mechanisms include endothelial dysfunction, oxidative stress, systemic inflammation and metabolic dysregulation [2]. Vascular calcification has recently received much attention because of its relationship with cardiovascular disease [3, 4]. Chronic inflammation may promote vascular calcification and recent studies have demonstrated a relationship between vascular calcification and endothelial dysfunction [5, 6].

Fetuin-A is a circulating protein mostly synthesised in the liver [7, 8] that is known to be an important inhibitor of vascular calcification and a potent anti-inflammatory cytokine [8–10]. Fetuin-A is considered to be a mediator that links chronic inflammation to cardiovascular diseases [11]. However, previous studies investigating the role of fetuin-A in patients with cardiovascular disease have published contradictory results [12]. Furthermore, several studies have proposed that serum fetuin-A levels are associated with the presence of the metabolic syndrome, suggesting fetuin-A as a risk factor for this condition [13].

Therefore, the aim of this study was to determine serum levels of fetuin-A in patients with OSAS and to examine the associations between fetuin-A levels and a number of conventional cardiovascular and metabolic risk factors.

The study population included 154 subjects admitted to the Hospital Universitari Son Espases sleep unit from January 2010 to December 2010. They had all been referred to the sleep laboratory for snoring or suspected OSAS. The case or control status was defined by the apnoea–hypopnoea index (AHI) threshold of ≥10.

No participant suffered from any other chronic disease (chronic obstructive pulmonary disease, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure and/or psychiatric disorders). The study was approved by the Hospital Universitari Son Espases Ethics Committee and all participants signed a consent form after being fully informed of the study goal and characteristics.

The diagnosis of OSAS was established by full polysomnography (E-Series; Compumedics Ltd, Abbotsford, Australia) that included recording of oronasal flow, thoracoabdominal movements, electrocardiography, submental and pretibial electromyography, electrooculography, electroencephalography and trancutaneous measurement of arterial oxygen saturation (Sa,O2). Apnoea was defined by the absence of airflow for >10 s. Hypopnoea was defined as any airflow reduction that lasted >10 s and resulted in arousal or oxygen desaturation. We considered desaturation a decrease in Sa,O2 >3%. The AHI was defined as the sum of the number of apnoeas plus hypopneas per hour of sleep. Excessive daytime sleepiness was quantified subjectively by the Epworth sleepiness scale. The occurrence of the metabolic syndrome was analysed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) clinical criteria [14]. The diagnosis of cardiovascular disease (myocardial infarction, unstable angina, coronary bypass or coronary angioplasty, stroke or transient ischaemic attack) was recorded according to the clinical history.

After fasting overnight, venous blood samples were obtained between 08:00 h and 10:00 h. Blood was centrifuged and serum was immediately separated into aliquots and stored at -80°C until analysis. Glucose, triglycerides, total cholesterol, HDL cholesterol, creatinine, AST, ALT and GGT were determined using standard enzymatic methods on a Hitachi Modular analyser (Roche Diagnostics, Indianapolis, IN, USA). The plasma levels of fetuin-A were determined by ELISA using a commercial kit (BioVender laboratory Medicine, GmbH, Heidelberg, Germany). Measurements were always performed in duplicate and mean values were used for analysis.

Results are presented as percentages, median or mean±sd. Parametric (unpaired t-test) and nonparametric tests (Wilcoxon test) were performed to assess the statistical significance of differences between groups. Correlations between variables were explored using the Spearman-rank test. To determine the independent effect of sleep apnoea on fetuin-A levels we used stepwise multiple regression analyses with study group (OSAS versus non-OSAS), AHI, arousal index, age, sex, body mass index (BMI), metabolic and cardiovascular risk factors as the independent variables and fetuin-A as the dependent variable. A p-value <0.05 was considered significant.

Characteristics of the study population are summarised in table 1. No differences were found for age, sex, BMI and waist circumference between patients with OSAS and controls. The prevalence of diabetes and metabolic syndrome was higher in the OSAS group than in the control group (p=0.006 and p=0.005).

View this table:
  • View inline
  • View popup
Table 1– Baseline characteristics and sleep profiles in controls and obstructive sleep apnoea syndrome (OSAS) patients

Compared with controls subjects, OSAS patients showed abnormal plasma levels of glucose and GGT. Fetuin-A levels were significantly lower in patients with OSAS than in subjects without OSAS (368±66 versus 445±53 ng·mL−1, p=0.015). Fetuin-A levels were significantly related to AHI (r= -0.226, p=0.006) and to the arousal index (r= -0.236, p=0.010). In multivariate analysis, study group and AHI were significantly associated with fetuin-A levels (p=0.034 and p=0.041, respectively).

We categorised all subjects into fetuin-A tertiles: 1) <332 ng·dL−1, 2) 332–431 ng·dL−1, and 3) >431 ng·dL−1. Fetuin-A levels were inversely associated with the prevalence of OSAS: first tertile, 88%; second tertile, 81%; and third tertile, 60% (p=0.012). Patients with OSAS and a history of cardiovascular disease revealed a trend towards lower levels of fetuin-A compared with patients without prevalent cardiovascular disease (364±97 versus 402±159 ng·mL−1, p=0.07). Fetuin-A levels did not differ between patients with and without diabetes (383±93 versus 387±147 ng·mL−1, p=0.892) or metabolic syndrome (373±131 versus 394±147 ng·mL−1, p=0.483).

This study shows that circulating fetuin-A levels are decreased in patients with OSAS and that they are associated with OSAS severity. These observations suggest that fetuin-A could be one of the contributing factors for the development of cardiovascular complications in OSAS patients.

The high cardiovascular mortality and morbidity rates in patients with OSAS are only partially explained by the high prevalence of traditional cardiovascular risk factors [2]. Accumulating evidence suggests that inflammatory balance and especially anti-inflammatory factors are determinants for the prognosis of atherosclerotic disease [15, 16]. However, recent studies have demonstrated that the prevalence and extent of vascular calcification is a strong predictor of cardiovascular events [17–19].

Fetuin-A deficiency is a potential missing link between a state of chronic inflammation and high incidence of cardiovascular events and mortality [20]. Fetuin-A is an anti-inflammatory mediator that participates in macrophage deactivation and inhibition of apoptosis of vascular smooth muscle cells [9]. In addition, fetuin-A complexes with calcium and phosphorus in the circulation and protects against vascular calcification [8, 9]. In this study, fetuin-A levels were significantly lower in OSAS patients than in subjects without OSAS. The mechanisms that support a relationship between OSAS and a decrease in the levels of fetuin-A are not known. We found a significant correlation between fetuin-A levels and AHI and arousal index suggesting that intermittent hypoxia and sleep fragmentation may influence the synthesis and the rate of fetuin-A release into the circulation. However, low fetuin-A levels in OSAS patients could be a consequence of the chronic inflammation that characterises OSAS. Patients with OSAS tend to be in a state of microinflammation in which downregulation of proteins such as fetuin-A may be expected. As chronic inflammation may contribute to fetuin-A depletion, it is plausible that serum fetuin-A levels may represent a useful marker for the prediction of clinical outcome in OSAS patients.

Functions and regulatory mechanisms of fetuin-A seem to differ according to the pathophysiological characteristics of the population studied. Fetuin-A was shown to act as a natural inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle and different studies have suggested that high fetuin-A levels are associated with the presence or development of metabolic syndrome [13].

In this study, we controlled for most potential confounding factors and found no attenuation of the inverse association of fetuin-A with OSAS. Furthermore, patients with a history of cardiovascular disease showed lower levels of fetuin-A compared with patients without prevalent cardiovascular disease but differences just failed to reach the statistical level of significance. These observations suggest that the effects of fetuin-A may be of greater importance in the cardiovascular risk of these patients independent of metabolic factors.

Taken together our results suggest a mechanistic relationship between changes in fetuin A production or release and OSAS. It is also possible that lower fetuin-A levels might reflect the presence of advanced atherosclerosis with calcification in patients with OSAS and could imply a novel link between OSAS and increased cardiovascular risk. Additional studies are needed to clarify the significance of these findings.

Several limitations should be considered. First, we did not evaluate biomarkers of inflammation so we could not investigate potential relationships between them and fetuin-A. Secondly, we did not measure the plasma levels of fetuin-A after continuous positive airway pressure and this may be a limitation in the assessment of the independent effects of OSAS on this marker. Thirdly, the number of subjects was limited, thus studies in larger populations are needed to confirm our data.

This study shows that plasma fetuin-A levels are decreased in OSAS. Future studies are needed to determine if low fetuin-A levels are related to the pathogenesis of cardiovascular risk in OSAS.

Footnotes

  • Support Statement

    Funding was provided, in part, by Instituto de Salud Carlos III; Fondo de Investigaciones Sanitarias.

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Marin JM,
    2. Carrizo SJ,
    3. Vicente E,
    4. et al
    . Long term cardiovascular outcomes in men with obstructive sleep apnea. Effects of treatment with CPAP. Lancet 2005; 365: 1046–1053.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Pack AI,
    2. Gislason T
    . Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 2009; 51: 434–451.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Demer LL,
    2. Tintut Y
    . Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938–2948.
    OpenUrlFREE Full Text
  4. ↵
    1. Sage AP,
    2. Tintut Y,
    3. Demer LL
    . Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7: 528–536.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Schindler TH,
    2. Cadenas J,
    3. Facta AD,
    4. et al
    . Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus. Eur Heart J 2009; 30: 3064–3073.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Abedin M,
    2. Tintut Y,
    3. Demer LL
    . Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161–1170.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Lim P,
    2. Collet JP,
    3. Moutereau S,
    4. et al
    . Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 2007; 53: 1835–1840.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Rezg R,
    2. Barreto FC,
    3. Barreto DV,
    4. et al
    . Inhibitors of vascular calcification as potential therapeutic targets. J Nephrol 2011; 24: 416–427.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Schafer C,
    2. Heiss A,
    3. Schwarz A,
    4. et al
    . The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–366.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Jahnen-Dechent W,
    2. Heiss A,
    3. Schafer C,
    4. et al
    . Fetuin-A regulation of calcified matrix metabolism. Circ Res 2011; 108: 1494–1509.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Bilgir O,
    2. Kebapcilar L,
    3. Bilgir F,
    4. et al
    . Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 2010; 49: 1281–1285.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Roos M,
    2. von Eynatten M,
    3. Heemann U,
    4. et al
    . Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol 2010; 105: 1666–1672.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ix JH,
    2. Shlipak MG,
    3. Brandenburg VM,
    4. et al
    . Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006; 113: 1760–1767.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, National Institutes of Health 2001. NIH Publication 01-3670.
  15. ↵
    1. Suliman ME,
    2. Garcia-Lopez E,
    3. Anderstam B,
    4. et al
    . Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem 2008; 46: 217–262.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Tsirpanlis G
    . Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif 2007; 25: 179–182.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Giachelli CM
    . Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959–2964.
    OpenUrlAbstract/FREE Full Text
    1. Olson JC,
    2. Edmundowicz D,
    3. Becker DJ,
    4. et al
    . Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000; 49: 1571–1578.
    OpenUrlAbstract
  18. ↵
    1. London GM,
    2. Guerin AP,
    3. Marchais SJ,
    4. et al
    . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731–1740.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Ketteler M,
    2. Bongartz P,
    3. Westenfeld R,
    4. et al
    . Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–833.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 4 Table of Contents
European Respiratory Journal: 40 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea
Antonia Barceló, Javier Piérola, Cristina Esquinas, Mónica de la Peña, Meritxell Arqué, Manuel Sánchez-de la Torre, Alberto Alonso-Fernandez, Ferran Barbé
European Respiratory Journal Oct 2012, 40 (4) 1046-1048; DOI: 10.1183/09031936.00011912

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea
Antonia Barceló, Javier Piérola, Cristina Esquinas, Mónica de la Peña, Meritxell Arqué, Manuel Sánchez-de la Torre, Alberto Alonso-Fernandez, Ferran Barbé
European Respiratory Journal Oct 2012, 40 (4) 1046-1048; DOI: 10.1183/09031936.00011912
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Sleep medicine
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pneumomediastinum and dehydration in cystic fibrosis
  • How can we achieve better prevention of TB among contacts?
  • Predictors of treatment outcome in MDR-TB in Portugal
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society